TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of MBSR in Early Stage Breast Cancer Recovery
Brief Summary: The purpose of this study was two-fold: (i) to assess whether MBSR favorably influences psychological status, quality of life, stress hormones, and immune status in breast cancer survivors; and (ii) to explore possible mechanisms by which MBSR may favorably influence these outcomes, in particular, through reduction in fear of breast cancer recurrence and associated perceived stress. Both objectives were studied at the critical transition time immediately following completion of surgical, radiation and/or chemotherapy therapy for breast cancer.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-Based Stress Reduction | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness-Based Stress Reduction; Assigned to Arm(s): 1
B: Arm Label: Acupuncture & educ; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Acupuncture and patient education | Arm Label: 2. Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Acupuncture and patient education; Assigned to Arm(s): Acupuncture & educ
C: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SCP care; Type: EXPERIMENTAL; Interventions: Other: SCP care | Intervention Type: OTHER; Name: SCP care; Assigned to Arm(s): SCP care
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: CBT and relaxation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: CBT and physical activity | Arm Label: 4; Type: NO_INTERVENTION; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: CBT and relaxation; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: CBT and physical activity; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study of the Effect of Hyperbaric Oxygen Treatment on Behavioral and Biomarker Measures in Children With Autism
Brief Summary: The purpose of this study is to increase the understanding of the effect of Hyperbaric Oxygen Treatment (HBOT) on the behavior and functioning of children with autism. The main goal of this study is to demonstrate that HBOT is safe and tolerable in autistic children, and to measure the effect of HBOT on specific chemicals in their blood that may play a role in the child's behavior.


Options:
A: Intervention Type: DEVICE; Name: Hyperbaric Oxygen Therapy; Assigned to Arm(s): N/A
B: Arm Label: Treatment- HBOT; Type: EXPERIMENTAL; Interventions: Procedure: Hyperbaric Oxygen Therapy (HBOT) | Arm Label: control-HBOT; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Hyperbaric Oxygen Therapy (HBOT); Assigned to Arm(s): Treatment- HBOT
C: Intervention Type: PROCEDURE; Name: Hyperbaric Therapy; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Hyperbaric Oxygen Treatment (HBOT) | Intervention Type: OTHER; Name: Hyperbaric Oxygen Treatment (HBOT); Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Arterial pH on N-balances of Patients Undergoing Automated Peritoneal Dialysis
Brief Summary: This study will test the hypothesis that by slightly lowering the acidity of blood (or increasing the pH), dialysis patients utilize protein and amino acids more efficiently.


Options:
A: Arm Label: Rosuvastatin 10mg; Type: EXPERIMENTAL; Interventions: Drug: 10mg Rosuvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 10mg Rosuvastatin; Assigned to Arm(s): Rosuvastatin 10mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Low normal pH (arterial pH 7.36-7.38); Type: ACTIVE_COMPARATOR; Interventions: Drug: ammonium chloride or sodium citrate/citric acid | Arm Label: High Normal pH (arterial pH 7.44-7.46); Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium citrate/citratic acid | Intervention Type: DRUG; Name: ammonium chloride or sodium citrate/citric acid; Assigned to Arm(s): Low normal pH (arterial pH 7.36-7.38) | Intervention Type: DRUG; Name: Sodium citrate/citratic acid; Assigned to Arm(s): High Normal pH (arterial pH 7.44-7.46)
C: Arm Label: Conventional hemodialysis; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional hemodialysis | Arm Label: Frequent hemodialysis; Type: EXPERIMENTAL; Interventions: Device: Frequent hemodialysis | Intervention Type: DEVICE; Name: Conventional hemodialysis; Assigned to Arm(s): Conventional hemodialysis | Intervention Type: DEVICE; Name: Frequent hemodialysis; Assigned to Arm(s): Frequent hemodialysis
D: Arm Label: 1: low flux hemodialysis; Type: OTHER; Interventions: Procedure: low flux hemodialysis | Arm Label: 2 on-line hemodiafiltration; Type: ACTIVE_COMPARATOR; Interventions: Procedure: on-line hemodiafiltration | Intervention Type: PROCEDURE; Name: on-line hemodiafiltration; Assigned to Arm(s): 2 on-line hemodiafiltration | Intervention Type: PROCEDURE; Name: low flux hemodialysis; Assigned to Arm(s): 1: low flux hemodialysis

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety/Tolerability of Methylphenidate Transdermal System (MTS) for Before-School Dysfunction in Children With Attention Deficit Hyperactivity Disorder (ADHD)
Brief Summary: The purpose of this study is to investigate the effectiveness of a medication skin patch called Methylphenidate Transdermal System (MTS). We will compare the MTS medicated patch to a placebo patch. We want to find out how well it treats ADHD during the early morning hours before a child leaves for school or summertime routines.


Options:
A: Arm Label: Methylphenidate Transdermal System (MTS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System (MTS) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: BEHAVIORAL; Name: Psychosocial treatment; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Anti-ADHD medication; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Assessment-and-Referral; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CONCERTA (methylphenidate HCl) / Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Placebo/ CONCERTA (methylphenidate HCl) | Intervention Type: DRUG; Name: Placebo/ CONCERTA (methylphenidate HCl); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CONCERTA (methylphenidate HCl) / Placebo; Assigned to Arm(s): 1
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Low Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Arm Label: Medium Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Arm Label: High Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Low Dose Methylphenidate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Medium Dose Methylphenidate | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): High Dose Methylphenidate

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety/Tolerability of Methylphenidate Transdermal System (MTS) for Before-School Dysfunction in Children With Attention Deficit Hyperactivity Disorder (ADHD)
Brief Summary: The purpose of this study is to investigate the effectiveness of a medication skin patch called Methylphenidate Transdermal System (MTS). We will compare the MTS medicated patch to a placebo patch. We want to find out how well it treats ADHD during the early morning hours before a child leaves for school or summertime routines.


Options:
A: Arm Label: Cannabis oil high dose; Type: EXPERIMENTAL; Interventions: Drug: Tetrahydrocannabinol | Arm Label: Cannabis oil low dose; Type: EXPERIMENTAL; Interventions: Drug: Tetrahydrocannabinol | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dummy oromucosal | Intervention Type: DRUG; Name: Tetrahydrocannabinol; Assigned to Arm(s): Cannabis oil high dose, Cannabis oil low dose | Intervention Type: DRUG; Name: Dummy oromucosal; Assigned to Arm(s): Control
B: Arm Label: Pain medication: diclofenac and atropine; Type: EXPERIMENTAL; Interventions: Drug: Diclofenac and Atropine combination drug | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Diclofenac and Atropine combination drug; Assigned to Arm(s): Pain medication: diclofenac and atropine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Ritalin LA; Type: EXPERIMENTAL; Interventions: Drug: Ritalin LA (methylphenidate hydrochloride extended release) | Intervention Type: DRUG; Name: Ritalin LA (methylphenidate hydrochloride extended release); Assigned to Arm(s): Ritalin LA
D: Arm Label: Methylphenidate Transdermal System (MTS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System (MTS) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Supporting the Health of Adults Undergoing Orthopedic Surgery During the Recovery Period
Brief Summary: Delirium (acute confusion) is a highly prevalent condition among hospitalized elders with substantial morbidity within the hospital and beyond. Particular patient populations are at high risk for poor outcomes after an episode of delirium. Patients with hip and other long bone fractures are at increased risk of developing delirium (acute confusion) which impedes functional recovery. This is a pilot study to test the tolerability and efficacy of donepezil, a cholinesterase inhibitor medication used commonly in persons with dementia, for the prevention of new or worsening delirium in aged hip and other long-bone fracture patients. Additional purposes involve gathering a small amount of patients' serum to better understand the pathophysiology of delirium in this population.

The purposes of this pilot study are to determine: 1) the safety and tolerability a cholinesterase inhibitor medication) in aged hip and long bone fracture patients, 2) To obtain estimates of subject accrual and preliminary estimates of effect size on the development of new delirium symptoms to allow for planning of a larger, definitive trial, 3) To better understand the underlying causes of delirium by examining whether a measure of blood anticholinergic activity relates to the incidence and persistence of delirium symptoms, and 4) To explore the interaction between anticholinergic activity, donepezil therapy, and delirium symptoms.


Options:
A: Arm Label: Inhalational anesthetic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Inhalational anesthetic | Arm Label: Intravenous anesthetic, propofol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous anesthetic, propofol | Intervention Type: DRUG; Name: Inhalational anesthetic; Assigned to Arm(s): Inhalational anesthetic | Intervention Type: DRUG; Name: Intravenous anesthetic, propofol; Assigned to Arm(s): Intravenous anesthetic, propofol
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: donepezil | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: donepezil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Liberal (10 g/dL) Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Biological: Liberal (10 g/dL) Transfusion Strategy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Restrictive (Symptomatic) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Liberal (10 g/dL) Transfusion Strategy; Assigned to Arm(s): Liberal (10 g/dL) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Restrictive (Symptomatic) Transfusion Strategy; Assigned to Arm(s): 2
D: Arm Label: Xenon; Type: EXPERIMENTAL; Interventions: Drug: Xenon | Arm Label: Sevoflurane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevoflurane | Intervention Type: DRUG; Name: Xenon; Assigned to Arm(s): Xenon | Intervention Type: DRUG; Name: Sevoflurane; Assigned to Arm(s): Sevoflurane

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Trial of a Clinical Algorithm to Predict the Loading Dose of Phenprocoumon
Brief Summary: Oral anticoagulation is often initiated in hospitalized patients. Although the therapeutic range of phenprocoumon is narrow, the individual drug demands unfortunately vary greatly between persons. Our group recently developed two dosing algorithms for the initiation of anticoagulation based on clinical predictors such as age, gender, body weight and laboratory values.

The aim of the proposed study is to prospectively evaluate the efficacy and safety of these two algorithms in medical and orthopedic inpatients, as well as in a group of outpatients and possibly in a geriatric collective.


Options:
A: Intervention Type: DEVICE; Name: Electronic Medical Record (EMR) to clinician's in-basket; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Automated Voice Message (AVM) reminder to patient's phone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Pharmacy Team phone call-letter followup; Assigned to Arm(s): N/A
B: Arm Label: A - coded unit ID; Type: EXPERIMENTAL; Interventions: Other: clinical decision support | Arm Label: B - coded unit ID; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: clinical decision support; Assigned to Arm(s): A - coded unit ID
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: Algorithm for phenprocoumon | Arm Label: B; Type: EXPERIMENTAL; Interventions: Other: algorithm for phenprocoumon | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Phenprocoumon | Intervention Type: OTHER; Name: Algorithm for phenprocoumon; Assigned to Arm(s): A | Intervention Type: OTHER; Name: algorithm for phenprocoumon; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Phenprocoumon; Assigned to Arm(s): C
D: Intervention Type: DRUG; Name: somatropin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multidimensional Intervention in Early Osteoarthritis (The Knee Study)
Brief Summary: Osteoarthritis (OA) is the most common joint-related disease and most prevalent form of arthritis in the United States. Pain relievers and anti-inflammatory medications are the most commonly prescribed treatments for OA. These medications, however, cannot completely alleviate OA symptoms. Additional recommended strategies for managing OA include physical and occupational therapy, exercise, and patient education. This study will compare the effectiveness of a physical training program, a self-management training program, and a program including both physical and self-management training for improving physical function in people with early stage knee OA.


Options:
A: Intervention Type: BEHAVIORAL; Name: self-management program; Assigned to Arm(s): N/A
B: Arm Label: Health Education Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Education | Arm Label: Usual Medical Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Osteoarthritis Self-Management; Type: EXPERIMENTAL; Interventions: Behavioral: Osteoarthritis Self-Management | Intervention Type: BEHAVIORAL; Name: Health Education; Assigned to Arm(s): Health Education Intervention | Intervention Type: BEHAVIORAL; Name: Osteoarthritis Self-Management; Assigned to Arm(s): Osteoarthritis Self-Management
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical training program | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-management training program | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical training and self-management training programs | Intervention Type: OTHER; Name: Physical training program; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Self-management training program; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Physical training and self-management training programs; Assigned to Arm(s): 3
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Patient Behavioral Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Patient Behavioral Intervention for OA | Arm Label: Provider Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Provider Intervention for OA | Arm Label: Patient and Provider Interventions; Type: EXPERIMENTAL; Interventions: Behavioral: Combined Patient and Provider Interventions for OA | Intervention Type: BEHAVIORAL; Name: Patient Behavioral Intervention for OA; Assigned to Arm(s): Patient Behavioral Intervention | Intervention Type: BEHAVIORAL; Name: Provider Intervention for OA; Assigned to Arm(s): Provider Intervention | Intervention Type: BEHAVIORAL; Name: Combined Patient and Provider Interventions for OA; Assigned to Arm(s): Patient and Provider Interventions

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in Adult Human Immunodeficiency Virus (HIV) Infected Female Subjects
Brief Summary: Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. The current study is designed to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV vaccine 580299 in HIV infected adult females living in the Republic of South Africa. The study is double blinded, randomized for HIV positive subjects and open for HIV negative subjects. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: CervarixTM | Arm Label: Placebo Group; Type: EXPERIMENTAL; Interventions: Other: Control | Intervention Type: BIOLOGICAL; Name: CervarixTM; Assigned to Arm(s): Cervarix Group | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Placebo Group
B: Arm Label: HIV+/Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Arm Label: HIV+/Aluminium Hydroxide Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Placebo Control | Arm Label: HIV-/Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): HIV+/Cervarix Group, HIV-/Cervarix Group | Intervention Type: BIOLOGICAL; Name: Placebo Control; Assigned to Arm(s): HIV+/Aluminium Hydroxide Group
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM), Biological: Placebo | Arm Label: Gardasil Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gardasil ® (Merck & Co. Inc), Biological: Placebo | Intervention Type: BIOLOGICAL; Name: GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM); Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Gardasil ® (Merck & Co. Inc); Assigned to Arm(s): Gardasil Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Gardasil Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Cervarix Group
D: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, Procedure: Collection of cervical specimen, Biological: Cervarix | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Blood sampling, Procedure: Collection of cervical specimen | Intervention Type: PROCEDURE; Name: Blood sampling; Assigned to Arm(s): Cervarix Group, Placebo Group | Intervention Type: PROCEDURE; Name: Collection of cervical specimen; Assigned to Arm(s): Cervarix Group, Placebo Group | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comprehensive Magnetic Resonance of Peripheral Arterial Disease
Brief Summary: The purpose of this study is to develop new ways of imaging fatty blockages in the leg arteries to improve upon techniques used now and to develop new ways of understanding how new treatments may affect the disease.


Options:
A: Arm Label: Randomized; Type: EXPERIMENTAL; Interventions: Drug: Simvastatin, Drug: Simvastatin/Ezetimibe | Arm Label: Ezetemibe; Type: EXPERIMENTAL; Interventions: Drug: Ezetimibe | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Randomized | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetemibe | Intervention Type: DRUG; Name: Simvastatin/Ezetimibe; Assigned to Arm(s): Randomized
B: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to Evolocumab, Other: Placebo to Ezetimibe | Arm Label: Placebo QM; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to Evolocumab, Other: Placebo to Ezetimibe | Arm Label: Ezetimibe (Q2W); Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Biological: Placebo to Evolocumab | Arm Label: Ezetimibe (QM); Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Biological: Placebo to Evolocumab | Arm Label: Evolocumab Q2W; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab, Other: Placebo to Ezetimibe | Arm Label: Evolocumab QM; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab, Other: Placebo to Ezetimibe | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab Q2W, Evolocumab QM | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe (Q2W), Ezetimibe (QM) | Intervention Type: BIOLOGICAL; Name: Placebo to Evolocumab; Assigned to Arm(s): Ezetimibe (Q2W), Ezetimibe (QM), Placebo Q2W, Placebo QM | Intervention Type: OTHER; Name: Placebo to Ezetimibe; Assigned to Arm(s): Evolocumab Q2W, Evolocumab QM, Placebo Q2W, Placebo QM
C: Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): N/A
D: Arm Label: Alirocumab 75 /up to 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Placebo (for ezetimibe), Drug: Lipid Modifying Therapy (LMT) | Arm Label: Ezetimibe 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Ezetimibe, Drug: Lipid Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Placebo (for ezetimibe); Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W | Intervention Type: DRUG; Name: Lipid Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W, Ezetimibe 10 mg

Answer: A